Abstract: Immunogenic modulators and compositions comprising oligonucleotide agents capable of inhibiting suppression of immune response by reducing expression of one or more gene involved with an immune response suppression mechanism.

Abstract: Immunogenic modulators and compositions comprising oligonucleotide agents capable of inhibiting suppression of immune response by reducing expression of one or more gene involved with an immune suppression mechanism.

Abstract: The disclosure relates, in some aspects, to methods and compositions for production of immunogenic compositions. In some embodiments, the disclosure provides host cells which have been treated ex vivo with one or more oligonucleotide agents capable of controlling and/or reducing the differentiation of the host cell. In some embodiments, compositions and methods described by the disclosure are useful as immunogenic modulators for treating cancer.

Abstract: Immunogenic modulators and compositions comprising oligonucleotide agents capable of inhibiting suppression of immune response by reducing expression of one or more gene involved with an immune suppression mechanism.

Abstract: The present invention comprises novel compositions and methods for the treatment of neurological diseases associated with beta amyloid peptide. In particular, the present invention is directed to A? fiber solubilization, for the treatment of amyloid-associated diseases such as Alzheimer's disease, and is described herein as being achieved by using small molecules binding to A? fiber The present invention further comprises novel methods of designing and screening compositions for the treatment of neurological disease wherein the design aspect comprises the modeling of molecular scaffolds having optimal structural characteristics that enable the development of small molecule compositions of non-peptide nature having desirable solubilization effects on amyloid plaques. In one embodiment, the design of the compounds comprises a molecular structure with three chemical domains that include a melatonin-like domain, a nicotine-like domain and a peptide-like domain for binding to A?.

Abstract: A prosthesis adapted for inter-luminal placement by endovascular deployment for the treatment of vascular dissection, the prosthesis has a self expanding stents (38) connected together to define an elongate lumen wall engaging surface. At least one of the stents has a bio-compatible graft material cover (36) to define a covered portion (25). The cover is adapted to close off a rupture (7) in the wall of the lumen (6) and the stents are adapted to provided pressure on the wall of the lumen adjacent to and extending away from the rupture.

Abstract: The present invention comprises novel compositions and methods for the treatment of Alzheimer's disease. In particular, the present invention is directed to A? fiber solubilization, for the treatment of Alzheimer's disease, and is described herein as being achieved by using small molecules of non-peptide nature.